Record October CyPath Lung Volume Underscores Adoption, but Financial Concerns Persist

What happened

bioAffinity announced record monthly testing volume for CyPath Lung in October 2026, continuing a pattern of strong year-over-year growth in test orders. This follows similar announcements in April and July, indicating sustained adoption momentum among physician offices. However, the press release provides no financial details on revenue or profitability, making it difficult to assess whether this volume growth is translating into improved consolidated financials. The company's latest quarterly report showed total revenue still declining and operating cash burn exceeding $3 million, with going-concern warnings. While the October datapoint is positive, it does not address the central challenge of scaling revenue fast enough to avoid further dilution.

Implication

The record October volume reinforces that CyPath Lung is gaining traction with physicians, but without accompanying revenue guidance or margin data, it offers limited insight into financial sustainability. The company's most recent quarter showed consolidated revenue falling 36% despite CyPath growth, indicating that discontinued services still weigh heavily. With cash burn over $3 million per quarter and only $2.6 million raised in June, the company may need additional capital before achieving scale. Unless management demonstrates in upcoming filings that CyPath revenue can offset the drag and reduce burn, the stock's risk profile remains unchanged. Maintain a wait-and-see approach until quarterly results confirm that volume is converting into profitable revenue growth.

Thesis delta

The investment thesis remains WAIT. Record October testing volume is consistent with the previously identified positive adoption trend for CyPath Lung, but it does not alter the core concern that the company's consolidated revenue is shrinking and cash burn remains unsustainable. The thesis will only improve if quarterly financials show CyPath revenue exceeding $500K and total revenue returning to growth, which is not confirmed by this announcement.